Author/Authors :
Shariati, Mahboube Department of Clinical Biochemistry - Isfahan Pharmaceutical Sciences Research Center - School of Pharmacy and Pharmaceutics Sciences - Isfahan University of Medical Sciences, Isfahan , Aghaei, Mahmoud Department of Clinical Biochemistry - Isfahan Pharmaceutical Sciences Research Center - School of Pharmacy and Pharmaceutics Sciences - Isfahan University of Medical Sciences, Isfahan , Movahedian, Ahmad Department of Clinical Biochemistry - Isfahan Pharmaceutical Sciences Research Center - School of Pharmacy and Pharmaceutics Sciences - Isfahan University of Medical Sciences, Isfahan , Somi, Mohammad Hosein Tabriz Liver and Gastrointestinal Disease Research Center , Dolatkhah, Homayun Tabriz Liver and Gastrointestinal Disease Research Center , Aghazade, Ahmad Mirza Department of Basic Sciences - Tabriz University of Medical Sciences, Tabriz
Abstract :
Background: Studies show that polyunsaturated fatty acids (PUFAs) may have an inhibitory role in carcinogenesis. It was previously
shown that PLA2 group 2A (PLA2G2A) messenger RNA (mRNA) expression is associated with less frequent metastasis and longer
survival in gastric adenocarcinoma. This study intends to investigate the effect of PUFAs on the expression of PLA2G2A in patients
with gastric cancer. Materials and Methods: Thirty-four patients with gastric cancer (GC) were randomly divided into two groups.
The first group received cisplatin medication. The second group received cisplatin medication and supplements of ω-fatty acids for
three courses. The total RNA was extracted from the tissues and cDNA was synthesized. The gene expression of PLA2G2A was
evaluated by the real-time polymerase chain reaction (PCR) method. To confirm the changes in gene expression, frozen section
was utilized. The frozen tissue samples were sectioned and stained using the immunohistochemistry technique. Results: After
chemotherapy and chemotherapy plus supplement, the relative mean of PLA2G2A gene expression increased 1.5 ± 0.5-fold and
7.4 ± 2.6-fold, respectively (P = 0.006). The relative mean of gene expression in patients who received cisplatin and ω-fatty acids
supplement increased more significantly (7.5 ± 3.3-fold) than in patients who received only cisplatin (P = 0.016). Conclusion: It was
found that PUFAs increased the gene and protein expression of PLA2G2A in gastric cancer. Concerning the fact that studies reveal
protective function of PLA2G2A in gastric cancer, it is suggested that increased expression of PLA2G2A is helpful. Furthermore,
PUFAs can be considered as a useful therapeutic supplement for patients with gastric cancer.